20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 7 of 7

Topic	Participants	Replies	Views	Activity
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…	+2	6	18k	17mo
Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues randomised trial On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…		2	50k	17mo
Revisiting: What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis CJC-1295 observational data needs a source GHRP class On the subject in the title: Revisiting: What a well-designed human trial of a secretagogue would look like Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it…	+69	74	25k	18mo
Second pass at: Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema Closed Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+15	19	22k	18mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+101	111	1.5k	18mo
What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 tesamorelin Solved What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…		2	7.2k	18mo
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing…	+15	19	930	18mo
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…	+48	52	59k	18mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of…	+130	137	11k	19mo
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide effect size type 2 diabetes randomised trial Solved Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…	+72	77	7.2k	19mo
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? Compounds › Repair & healing peptides TB-500 BPC-157 needs a source Closed TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022)…	+19	23	4.2k	19mo
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial Solved Closed Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…	+94	102	14k	19mo
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: STEP 1 ( N Engl J Med…	+9	13	42k	19mo
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide effect size randomised trial SELECT trial STEP programme Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+1	5	11k	20mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…	+58	62	49k	20mo
Reading a preclinical wound-healing model and its relevance to a human tendon Compounds › Repair & healing peptides TB-500 preprint observational data Wiki Closed On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support…	+149	160	3.3k	20mo
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds custom synthesis mislabelling research use only Solved Posting this under the heading it deserves: Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with…	+119	141	22k	20mo
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…	+7	11	5.5k	20mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide effect size SURMOUNT programme tirzepatide randomised trial Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-1…		2	23k	21mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? Compounds › Oral incretins orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…	+23	27	4.8k	22mo
Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide TRIUMPH programme effect size preprint randomised trial Solved Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read…	+51	56	700	22mo
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins orforglipron SOUL trial PIONEER programme On the subject in the title: Orforglipron as a non-peptide: what changes when the molecule is small Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURMOUNT-4 ( JAMA ,…	+26	30	26k	23mo
The most common factual error about semaglutide on the internet Compounds › Semaglutide STEP programme randomised trial type 2 diabetes effect size On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…		2	49k	2y
Naming conventions for research peptides and the confusion they cause — one year on Compounds › Other compounds research use only mislabelling needs a source Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…	+1	5	181	2y
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…	+115	125	30k	2y